Search
Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing
Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.
Read moreYoungEHA Webinar on Burnouts: When caregivers become patients - talking about awareness
In order to create awareness for burnout symptoms among hematologists, the YoungEHA Committee has planned a webinar on burnouts to help professionals in hematology identify early signs and how to address this issue in a wider context.
Read moreEHA-EBMT 2nd European CAR T Cell Meeting
Dates: January 30 – February 1, 2020
Location: Sitges (Barcelona), Spain
Chairs: H Einsele, C Chabannon
The 2nd edition of this meeting is jointly organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).…
EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease
November 10-11, 2022 | Bordeaux, France
Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.
EHA Research Grant review and selection process
1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.
Read moreCongress Sponsor Program
Join us at the EHA Annual Congress, where you have the unique opportunity to connect and grow with a community of hematology experts.
Read moreChoose your membership
Wherever you are in the world, you can join our vibrant community and benefit from our rigorous resources and career-enhancing opportunities.
Read moreHARMONY: Better care of patients with hematologic malignancies kicked off!
“Combining data available from clinical trials as well as real world patients allows us to do more advanced analyses on possible treatment options that could be effective for individual patient or categories of patients”, said Jesús María Hernandez Rivas, Project…
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- »